POWER (Pulse Width Optimized Waveform Evaluation Trial)

Status Completed

Clinical Trial Summary

The objective of this study is to compare the ULV (Upper Limit of Vulnerability)/DFT (Defibrillation Threshold) efficacy between the 2.5, 3.5 and 4.5 ms membrane time constant based biphasic defibrillation waveforms. This comparison will result in identifying the optimal membrane time constant when programming the "tuned" defibrillation waveform.

Clinical Trial Description

Sudden cardiac death (SCD) continues to be a significant cause of cardiac mortality with annual deaths ranging from 250,000 to 400,000 in the United States. Accordingly, implantable cardioverter-defibrillators (ICD's) have proven to be an important therapeutic option for patients susceptible to SCD. Successful therapy and generator longevity are greatly dependent on proper defibrillation threshold (DFT) determination.

All modern ICD's utilize a biphasic waveform for defibrillation. It has been clearly shown that biphasic waveforms reduce the energy required for internal defibrillation of the heart. However, there is no consensus on which pulse widths are best for defibrillation.

St. Jude Medical ICD's (implantable cardioverter defibrillators) have programmable pulse widths, which allow the physician multiple options in dealing with ICD patients. By implanting ICD's with programmable pulse widths, this study utilizes the Tissue RC Resistance/Capacitance) model to try to identify the optimal pulse widths.

To determine the efficacy of an optimal membrane time constant estimate for the "tuned" waveform, defibrillation testing must be performed. Upper limit of vulnerability (ULV) has been proposed as an alternative means of predicting the DFT and it has been shown that ULV guided DFT testing can achieve a defibrillation success rate of 95%. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00311181
Study type	Interventional
Source	Abbott Medical Devices
Contact
Status	Completed
Phase	Phase 4
Start date	August 2006
Completion date	April 2008

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02923726` - Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP	N/A
Recruiting	`NCT05175937` - REal World Assessment for Patients Implanted With Implantable CardioverTer DefibrIllatOr Using Bluetooth Technology
Completed	`NCT02026102` - A Pilot Trial of Patient Decision Aids for Implantable Cardioverter-Defibrillators (ICDs)	N/A
Completed	`NCT01262508` - Development of Algorithms to Predict Hemodynamic Instability	N/A
Completed	`NCT00998218` - Effect of Ranolazine on Arrhythmias and Microvolt T- Wave Alternans (MVTWA) Patients With LV Dysfunction	Phase 3
Completed	`NCT00845286` - Marathon, Genetics, Inflammation and the Cardiovascular System: MAGIC-Trial	N/A
Active, not recruiting	`NCT00562757` - Prospective Study to Identify Patients at Risk of Dangerous Ventricular Arrhythmias	N/A
Completed	`NCT00622453` - Arrhythmias in Myotonic Muscular Dystrophy	N/A
Completed	`NCT03833843` - Sudden Cardiac Death in Systemic Right Ventricle
Completed	`NCT04024865` - Domperidone and Risk of Serious Cardiac Events in Postpartum Women
Recruiting	`NCT05799833` - Low QRS Voltages in Young Healthy Individuals and Athletes
Recruiting	`NCT05694572` - Post-market Surveillance of Micorport CRM Cardiac Implantable Electronic Devices
Not yet recruiting	`NCT03622307` - Subcutaneous ICD Therapy Combined With VT Ablation for the Secondary Prevention of Sudden Cardiac Death	N/A
Recruiting	`NCT02058771` - Utilising Lifemap to Investigate Malignant Arrhythmia Therapy
Recruiting	`NCT02056509` - The Effect of Chest Compression and Ventilation Coordination During Cardiopulmonary Resuscitation.	N/A
Terminated	`NCT01948206` - Study of Paced QRS Duration as a Marker of Sudden Cardiac Death	N/A
Completed	`NCT01227785` - Next Generation INCEPTA Implantable Cardioverter Defibrillator (ICD) and Cardiac Resynchronization Therapy (CRT-D) Field Following Study	N/A
Terminated	`NCT00524862` - Standard Drug Therapy vs. Implanted Defibrillator for Primary Prevention of Sudden Cardiac Death	N/A
Completed	`NCT00534300` - Intravenous n-3 Fatty Acids and Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillator (ICD)-Pacemaker	Phase 1/Phase 2
Recruiting	`NCT00181233` - Imaging Techniques for Identifying Factors of Sudden Cardiac Death Risk